Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves Β· freshest Wall Street data, updated daily View live feed β†’
Analyst Tracker/Terence Flynn
MS

Terence Flynn

Wall Street Analyst
β˜…β˜…β˜…β˜…β˜†
#875
on 13Foresight Β· ranked by our own returns
57%
Success Rate
+4.8%
Average Return
82 of 144 calls profitable Β· +1.7% vs benchmark
S&P 500 (SPY)
πŸ“ˆ Across the calls we could measure, roughly 57% of Terence Flynn's ratings turned a profit when each position was held for 2 year β€” averaging +4.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

126 Buy 103 Hold 14 Sell
Terence's Stock Coverage 40 ratings Β· 2026-11-04
Company Date Position Consensus β“˜ Price Target β“˜ 2-Yr Return vs S&P 500 β“˜
MRK
Merck & Company
Oct 30, 2026 BUY Strong Buy
-3.5% avg upside
44 analysts
$174.00
16.45% Upside
-0.8% Β·
GILD
Gilead Sciences
Oct 30, 2026 BUY Strong Buy
-27.3% avg upside
66 analysts
$183.00
7.24% Upside
-0.2% Β·
LLY
Eli Lilly & Co
Oct 30, 2026 BUY Strong Buy
-16.7% avg upside
50 analysts
$1596.00
12.69% Upside
-0.5% Β·
BMY
Bristol-Myers Squibb
Oct 30, 2026 SELL Buy
-2.2% avg upside
42 analysts
$40.00
36.02% Downside
-0.9% Β·
BIIB
Biogen
Oct 29, 2026 HOLD Strong Buy
+6.6% avg upside
53 analysts
$231.00
8.88% Downside
+1.9% Β·
BNTX
BioNTech SE
Oct 26, 2026 BUY Strong Buy
+48.9% avg upside
28 analysts
$114.00
29.39% Upside
+4.4% Β·
ABBV
AbbVie
Oct 22, 2026 BUY Strong Buy
-14.5% avg upside
47 analysts
$310.00
5.18% Upside
+3.0% Β·
RCUS
Arcus Biosciences
Oct 20, 2026 HOLD Strong Buy
+98.9% avg upside
22 analysts
$23.00
26.46% Upside
-24.8% Β·
NRIX
Nurix Therapeutics
Oct 15, 2026 BUY Strong Buy
+22.5% avg upside
28 analysts
$38.00
41.87% Upside
-36.1% Β·
JNJ
Johnson & Johnson
Oct 15, 2026 BUY Strong Buy
-9.1% avg upside
40 analysts
$292.00
6.98% Upside
+8.8% Β·
AMGN
Amgen
Oct 07, 2026 HOLD Buy
-29.9% avg upside
57 analysts
$359.00
23.06% Downside
+13.2% Β·
RPRX
Royalty Pharma
Oct 07, 2026 BUY Strong Buy
-12.2% avg upside
15 analysts
$67.00
0.19% Downside
+19.0% Β·
MRNA
Moderna
Oct 07, 2026 HOLD Hold
-48.5% avg upside
38 analysts
$95.00
57.17% Downside
+22.7% Β·
VRTX
Vertex Pharmaceuticals
Oct 07, 2026 BUY Strong Buy
-20.5% avg upside
62 analysts
$665.00
18.94% Upside
+9.4% Β·
UTHR
United Therapeutics
Oct 07, 2026 HOLD Buy
-22.7% avg upside
27 analysts
$566.00
5.45% Downside
+10.3% Β·
REGN
Regeneron
Oct 07, 2026 HOLD Strong Buy
-12.1% avg upside
60 analysts
$779.00
16.12% Downside
+29.5% Β·
PFE
Pfizer
Oct 07, 2026 HOLD Buy
+9.2% avg upside
46 analysts
$28.00
8.24% Downside
+9.5% Β·
ALMS
Alumis Inc.
Sep 02, 2026 BUY Strong Buy
+361.9% avg upside
11 analysts
$29.00
330.90% Upside
-36.7% Β·
LEGN
Legend Biotech
Aug 12, 2026 BUY Strong Buy
+182.2% avg upside
27 analysts
$48.00
121.90% Upside
+10.3% Β·
BHVN
Biohaven Ltd.
Aug 12, 2026 BUY Buy
+51.3% avg upside
25 analysts
$19.00
23.22% Upside
+6.4% Β·
ARVN
Arvinas Holding Company
Aug 10, 2026 HOLD Buy
+258.0% avg upside
28 analysts
$10.00
27.32% Upside
-17.5% Β·
GPCR
Structure Therapeutics, Inc. Sponsored ADR
Aug 10, 2026 BUY Strong Buy
+373.2% avg upside
17 analysts
$126.00
476.18% Upside
-62.0% Β·
PRME
Prime Medicine, Inc.
Aug 10, 2026 HOLD Strong Buy
+101.7% avg upside
18 analysts
β€” -1.7% Β·
NTLA
Intellia Therapeutics
Aug 10, 2026 HOLD Buy
+187.2% avg upside
39 analysts
$15.00
20.21% Upside
+2.4% Β·
OGN
Organon
Apr 10, 2026 HOLD Sell
+7.4% avg upside
9 analysts
$9.00
35.06% Downside
+57.2% Β·
CRSP
Crispr Therapeutics AG
Feb 17, 2026 SELL Buy
+45.6% avg upside
41 analysts
$33.00
35.78% Downside
+0.2% Β·
CCCC
C4 Therapeutics
Sep 21, 2025 HOLD Strong Buy
+405.9% avg upside
21 analysts
β€” +19.5% Β·
EDIT
Editas Medicine
Dec 13, 2024 HOLD Buy
+398.5% avg upside
33 analysts
β€” +103.5% Β·
ALKS
Alkermes
Jun 01, 2021 SELL Strong Buy
-3.4% avg upside
34 analysts
$16.00
64.63% Downside
-26.5% Β·
CTMX
CytomX Therapeutics
Aug 10, 2020 HOLD Strong Buy
+361.2% avg upside
21 analysts
$12.00
412.89% Upside
-79.1% Β·
DE:MRK
Merck KGaA
Aug 03, 2020 BUY Buy
-7.2% avg upside
34 analysts
$93.70
38.05% Downside
+72.1% Β·
TSE:BHC
Bausch Health Companies
Dec 02, 2019 HOLD Buy
+386.9% avg upside
30 analysts
$41.93
265.59% Upside
-20.8% Β·
KLDO
Kaleido Biosciences
Mar 25, 2019 BUY Buy
+13249900.0% avg upside
5 analysts
$20.00
19999899.92% Upside
Β· Β·
DNTH
Dianthus Therapeutics
Mar 25, 2019 HOLD Strong Buy
+23.4% avg upside
32 analysts
$16.00
80.59% Downside
-35.3% Β·
ALNY
Alnylam Pharma
Aug 13, 2018 BUY Strong Buy
+76.3% avg upside
53 analysts
$155.00
6.16% Downside
+51.1% Β·
KNSA
Kiniksa Pharmaceuticals
Jun 18, 2018 HOLD Strong Buy
-11.0% avg upside
12 analysts
$22.00
76.11% Downside
+40.2% Β·
KYNB
Kyntra Bio
Jul 21, 2017 HOLD Buy
+615.8% avg upside
17 analysts
$31.00
578.25% Upside
Β· Β·
AGIO
Agios Pharma
Jun 13, 2016 HOLD Strong Buy
+99.0% avg upside
30 analysts
$46.00
50.64% Upside
+77.6% Β·
ATRA
Atara Biotherapeutics
Nov 18, 2015 HOLD Buy
+125.8% avg upside
18 analysts
$38.00
374.31% Upside
Β· Β·
MCRB
Seres Therapeutics
Jul 21, 2015 HOLD Buy
+836.2% avg upside
11 analysts
$36.00
1933.95% Upside
Β· Β·
πŸ”’ 35 more ratings β€” with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Terence Flynn β€” Frequently Asked Questions
How accurate are Terence Flynn's stock ratings?
Based on the calls 13Foresight could measure, about 56% of Terence's ratings were profitable over a one-year hold, with an average return of +3.4% per rating, or +1.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Terence ranked on 13Foresight?
Terence Flynn is currently ranked #875 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge β€” so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Terence cover?
Terence most recently has ratings on MRK, GILD, LLY, BMY, BIIB, BNTX, ABBV, RCUS, NRIX, JNJ, AMGN, RPRX and 28 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.